このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Corcept Therapeutics 将来の成長

Future 基準チェック /46

Corcept Therapeuticsは、26%と13.2%でそれぞれ年率26%で利益と収益が成長すると予測される一方、EPSはgrowで23.1%年率。

主要情報

26.0%

収益成長率

23.1%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	13.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Jun 2024

今後の成長に関する最新情報

Recent updates

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09

業績と収益の成長予測

NasdaqCM:CORT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	788	216	N/A	276	3
12/31/2025	716	155	222	211	5
12/31/2024	632	109	157	158	5
3/31/2024	524	117	125	125	N/A
12/31/2023	482	105	127	127	N/A
9/30/2023	450	91	154	155	N/A
6/30/2023	428	94	135	135	N/A
3/31/2023	414	94	111	111	N/A
12/31/2022	402	101	120	120	N/A
9/30/2022	398	117	136	136	N/A
6/30/2022	392	113	151	151	N/A
3/31/2022	380	112	177	178	N/A
12/31/2021	366	113	167	168	N/A
9/30/2021	353	106	153	154	N/A
6/30/2021	343	98	134	135	N/A
3/31/2021	340	99	143	144	N/A
12/31/2020	354	106	151	152	N/A
9/30/2020	356	109	164	165	N/A
6/30/2020	351	114	173	173	N/A
3/31/2020	335	106	145	146	N/A
12/31/2019	306	94	135	136	N/A
9/30/2019	285	87	108	109	N/A
6/30/2019	268	78	114	115	N/A
3/31/2019	258	76	104	105	N/A
12/31/2018	251	75	115	116	N/A
9/30/2018	238	152	119	119	N/A
6/30/2018	216	148	85	85	N/A
3/31/2018	189	142	85	86	N/A
12/31/2017	159	129	N/A	61	N/A
9/30/2017	130	35	N/A	41	N/A
6/30/2017	109	24	N/A	39	N/A
3/31/2017	93	13	N/A	25	N/A
12/31/2016	81	8	N/A	18	N/A
9/30/2016	72	5	N/A	18	N/A
6/30/2016	64	1	N/A	10	N/A
3/31/2016	56	-2	N/A	8	N/A
12/31/2015	50	-6	N/A	3	N/A
9/30/2015	44	-11	N/A	-2	N/A
6/30/2015	38	-17	N/A	-9	N/A
3/31/2015	32	-22	N/A	-18	N/A
12/31/2014	27	-31	N/A	-27	N/A
9/30/2014	22	-39	N/A	-34	N/A
6/30/2014	17	-44	N/A	-36	N/A
3/31/2014	13	-48	N/A	-37	N/A
12/31/2013	10	-46	N/A	-37	N/A
9/30/2013	8	-46	N/A	-38	N/A
6/30/2013	6	-43	N/A	-39	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CORTの予測収益成長率 (年間26% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: CORTの収益 ( 26% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: CORTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: CORTの収益 ( 13.2% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CORTの収益 ( 13.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CORTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Corcept Therapeutics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 14% to US$49.70

Price target increased by 11% to US$39.60

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Consensus EPS estimates increase by 13%

Price target increased by 8.1% to US$36.83

Price target increased by 7.3% to US$32.92

Recent updates

Price target increased by 14% to US$49.70

Chief Development Officer notifies of intention to sell stock

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome)

President of Endocrinology notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

New minor risk - Shareholder dilution

Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024

Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Chief Accounting Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome

President of Endocrinology notifies of intention to sell stock

President of Endocrinology exercised options and sold US$364k worth of stock

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

President of Endocrinology notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial

Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024

Price target increased by 11% to US$39.60

New minor risk - Share price stability

Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology

Chief Scientific Officer exercised options and sold US$728k worth of stock

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Chief Development Officer notifies of intention to sell stock

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

President of Corcept Endocrinology notifies of intention to sell stock

Consensus EPS estimates increase by 13%

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Price target increased by 8.1% to US$36.83

President of Corcept Endocrinology notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis

Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023

President of Corcept Endocrinology exercised options and sold US$452k worth of stock

President of Corcept Endocrinology notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

President of Corcept Endocrinology notifies of intention to sell stock

Chief Scientific Officer recently sold US$632k worth of stock

Chief Scientific Officer exercised options and sold US$811k worth of stock

Investor sentiment improves as stock rises 22%

Price target increased by 7.3% to US$32.92

Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023

Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Chief Accounting Officer notifies of intention to sell stock

Chief Business Officer & Secretary recently sold US$1.1m worth of stock

Chief Business Officer & Secretary exercised options and sold US$1.3m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

First quarter 2023 earnings: EPS misses analyst expectations

Corcept Therapeutics Incorporated Revises Revenue Guidance for 2023

Insufficient new directors

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Price target decreased by 7.6% to US$31.60

Corcept Therapeutics Incorporated to Report Q4, 2022 Results on Feb 28, 2023

Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics Provides Miricorilant Clinical Development Update

Price target increased to US$35.00

Chief Business Officer & Secretary recently sold US$615k worth of stock

President of Corcept Endocrinology exercised options and sold US$557k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2022